Last reviewed · How we verify
NCT02912143: GEPHARD
German Pediatric Hemophilia Research Database
trial testing documentation only in Hemophilia A in 800 participants. Currently enrolling.
31 December 2027
Quick facts
| Lead sponsor | Goethe University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 800 |
| Start date | 1 January 2017 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2028 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- documentation only
Conditions studied
- Hemophilia A — all drugs for Hemophilia A →
- Hemophilia B — all drugs for Hemophilia B →
- Children — all drugs for Children →
- Drug Specific Antibodies — all drugs for Drug Specific Antibodies →
Sponsor
Goethe University
Who can join
Under 18, any sex, with Hemophilia A or Hemophilia B. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The German Pediatric Hemophilia Research Database will collect data on the prophylactic and therapeutic use of factor concentrates, complications, outcome measures (joint scores, QoL) and living circumstances in newly diagnosed children with hemophilia.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A Cross-sectional Analysis of Treatment in PUPs in 2021 in Germany - First Data from the GEPHARD Study Group.
GEPHARD Investigators, Contributors:, Contributors to the cross-sectional analysis:, Study commission. · · 2022 · cited 4× · PMID 36288733 · DOI 10.1055/s-0042-1757552
Verify or expand the search:
- PubMed search for NCT02912143
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hemophilia A
Currently open trials in the same condition.
- NCT07416526 — A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A · Phase 3 · recruiting
- NCT07416604 — A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A · Phase 3 · recruiting
- NCT07523399 — Joint Health, Balance and Quality of Life in Adults With Hemophilia A · recruiting
- NCT06833983 — To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A · Phase 3 · recruiting
- NCT06579144 — Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A · Phase 1 · recruiting
Other Goethe University trials
Trials by the same sponsor.
- NCT07422844 — Dynamic Network Response to TMS Treatment · recruiting
- NCT07008261 — Robot-assisted Cystectomies With Regard to Blood Loss, Pain and Transfusions. · recruiting
- NCT06879184 — Cohort of the Specialist Network Infectious Diseases · not yet recruiting
- NCT06201936 — EPIDURAL- Evaluation of Preexisting Information Regarding Neuroaxial Procedures for Labour Analgesia · recruiting
- NCT06627140 — Expected and Actual Preterm-Birth and Parental Distress: Impact on Children's Mental Health · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02912143 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Goethe University
- Last refreshed: 8 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02912143.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing